Two Sigma Investments
NKTR icon

Two Sigma Investments’s Nektar Therapeutics NKTR Stock Holding History

Two Sigma Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67M Buy
930,741
+457,727
+97% +$26.1M 0.05% 392
2025
Q4 		$20M Buy
473,014
+38,777
+9% +$2.17M 0.03% 721
2025
Q3 		$24.7M Buy
434,237
+354,842
+447% +$11.7M 0.04% 559
2025
Q2 		$2.05M Sell
79,395
-16,278
-17% -$183K ﹤0.01% 1816
2025
Q1 		$976K Sell
95,673
-6,817
-7% -$89.1K ﹤0.01% 2193
2024
Q4 		$1.43M Buy
102,490
+11,612
+13% +$205K ﹤0.01% 1951
2024
Q3 		$1.77M Sell
90,878
-29,734
-25% -$567K ﹤0.01% 1754
2024
Q2 		$2.24M Sell
120,612
-18,184
-13% -$383K 0.01% 1479
2024
Q1 		$1.94M Sell
138,796
-6,336
-4% -$66.3K ﹤0.01% 1506
2023
Q4 		$1.23M Sell
145,132
-41,205
-22% -$312K ﹤0.01% 1954
2023
Q3 		$1.66M Sell
186,337
-27,119
-13% -$261K ﹤0.01% 1542
2023
Q2 		$1.84M Buy
213,456
+78,359
+58% +$836K ﹤0.01% 1491
2023
Q1 		$1.42M Buy
135,097
+108,581
+409% +$3.29M ﹤0.01% 1651
2022
Q4 		$899K Sell
26,516
-29,602
-53% -$1.43M ﹤0.01% 1746
2022
Q3 		$2.69M Buy
56,118
+27,890
+99% +$1.66M 0.01% 1011
2022
Q2 		$1.61M Sell
28,228
-3,265
-10% -$206K 0.01% 1314
2022
Q1 		$2.55M Sell
31,493
-21,348
-40% -$3.16M 0.01% 1229
2021
Q4 		$10.7M Buy
52,841
+25,324
+92% +$5.49M 0.02% 748
2021
Q3 		$7.41M Buy
27,517
+1,313
+5% +$316K 0.02% 938
2021
Q2 		$6.75M Buy
26,204
+20,131
+331% +$5.57M 0.02% 1013
2021
Q1 		$1.82M Buy
6,073
+3,721
+158% +$1.16M ﹤0.01% 1780
2020
Q4 		$600K Sell
2,352
-12,596
-84% -$3.25M ﹤0.01% 2368
2020
Q3 		$3.72M Sell
14,948
-3,771
-20% -$1.19M 0.01% 944
2020
Q2 		$6.5M Buy
+18,719
New +$5.84M 0.03% 540
2020
Q1 		– Sell
-6,201
Closed -$2.01M – 3611
2019
Q4 		$2.01M Buy
+6,201
New +$1.8M 0.01% 1582
2019
Q3 		– Sell
-4,662
Closed -$2.49M – 3700
2019
Q2 		$2.49M Buy
+4,662
New +$2.34M 0.01% 1300
2019
Q1 		– Sell
-5,541
Closed -$2.73M – 3339
2018
Q4 		$2.73M Sell
5,541
-3,007
-35% -$1.82M 0.01% 1081
2018
Q3 		$7.82M Sell
8,548
-23,612
-73% -$20.2M 0.02% 751
2018
Q2 		$23.6M Buy
+32,160
New +$37.1M 0.07% 363
2017
Q3 		– Sell
-2,955
Closed -$924K – 3048
2017
Q2 		$866K Sell
2,955
-16,737
-85% -$4.84M ﹤0.01% 1994
2017
Q1 		$6.93M Sell
19,692
-47,907
-71% -$10.8M 0.02% 767
2016
Q4 		$12.4M Buy
67,599
+21,681
+47% +$4.41M 0.05% 455
2016
Q3 		$11.8M Buy
+45,918
New +$11.8M 0.04% 475
2015
Q1 		– Sell
-3,920
Closed -$912K – 2776
2014
Q4 		$912K Buy
+3,920
New +$838K 0.01% 1423
2013
Q4 		– Sell
-1,014
Closed -$159K – 2312
2013
Q3 		$159K Buy
+1,014
New +$187K ﹤0.01% 1693

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments's NKTR Position: Q1 2026 in Review

Two Sigma Investments increased its Nektar Therapeutics (NKTR) stake by 97% in Q1 2026, buying an estimated $26.1M and bringing the position to 930,741 shares worth $67M. The position accounts for 0.05% of the portfolio, ranked #392.

Two Sigma Investments first reported a position in NKTR in Q3 2013 and has held it in 35 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Two Sigma Investments held 930,741 shares of Nektar Therapeutics worth $67M as of Q1 2026.
  • Two Sigma Investments bought 457,727 Nektar Therapeutics shares in Q1 2026, an estimated $26.1M.
  • Nektar Therapeutics made up 0.05% of Two Sigma Investments's portfolio in Q1 2026, its #392 holding.
  • Two Sigma Investments first reported a position in Nektar Therapeutics in Q3 2013 and has held it in 35 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.